2.67

4.71% 0.12

After Hours: 2.61 -0.06 -2.25%

Zentalis Pharmaceuticals Inc (ZNTL)

Overview News Price History Option Chain Financials Why ZNTL Down? Discussions Forecast

Zentalis Pharmaceuticals Inc stock is traded at $2.67, with a volume of 428.41K. It is up +4.71% in the last 24 hours and up +8.10% over the past month. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Previous Close:

$2.55

Open:

$2.49

24h Volume:

428.41K

Relative Volume:

0.36

Market Cap:

$172.88M

Revenue:

$26.87M

Net Income/Loss:

$-149.32M

P/E Ratio:

-1.2816

EPS:

-2.0833

Net Cash Flow:

$-134.01M

1W Performance:

+4.30%

1M Performance:

+8.10%

6M Performance:

+72.26%

1Y Performance:

+51.70%

1-Day Range:

$2.49

$2.695

1-Week Range:

$2.405

$2.70

52-Week Range:

$1.01

$3.95

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name

Zentalis Pharmaceuticals Inc

Sector

Healthcare (1113)

Industry

Biotechnology (623)

Phone

(858) 263-4333

Address

10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY

Employee

166

Twitter

@ZentalisP

Next Earnings Date

2026-03-25

Latest SEC Filings

ZNTL's Discussions on Twitter

Compare ZNTL vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZNTL Zentalis Pharmaceuticals Inc	2.67	165.11M	26.87M	-149.32M	-134.01M	-2.0833
VRTX Vertex Pharmaceuticals Inc	453.74	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	756.73	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.16	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.83	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.60	31.97B	606.42M	-1.28B	-997.58M	-6.403

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-26	Resumed	Wells Fargo	Equal Weight
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral
Jun-20-24	Downgrade	UBS	Buy → Neutral
Jun-18-24	Downgrade	Jefferies	Buy → Hold
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight
Oct-07-21	Resumed	Jefferies	Buy
Sep-30-21	Initiated	Stifel	Buy
Sep-29-21	Initiated	Oppenheimer	Outperform
May-21-21	Initiated	UBS	Buy
Jan-20-21	Initiated	Wedbush	Outperform
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight
Aug-27-20	Initiated	H.C. Wainwright	Buy
Apr-28-20	Initiated	Guggenheim	Buy
Apr-28-20	Initiated	Jefferies	Buy
Apr-28-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Initiated	SVB Leerink	Outperform

View All

Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News

05:14 AM

Zentalis (ZNTL) centers strategy on azenosertib for Cyclin E1-positive ovarian cancer - Stock Titan

05:14 AM

04:55 AM

Zentalis Pharmaceuticals 10-K: $0 Revenue, $(137.1)M Net Loss - TradingView

04:55 AM

04:24 AM

Zentalis Pharmaceuticals (Nasdaq: ZNTL) cuts costs, extends cash runway into 2027 - Stock Titan

04:24 AM

04:05 AM

Cancer drug developer says cash lasts into late 2027 as key trial nears - Stock Titan

04:05 AM

Mar 22, 2026

Investment Recap: Can Zentalis Pharmaceuticals Inc expand its profit margins2026 Reactions & Weekly High Potential Alerts - baoquankhu1.vn

Mar 22, 2026

Mar 21, 2026

Aug Intraday: Can Zentalis Pharmaceuticals Inc keep up with sector leaders2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn

Mar 21, 2026

Profit Recap: Does Zentalis Pharmaceuticals Inc have a sustainable dividendEarnings Beat & Consistent Income Trade Ideas - baoquankhu1.vn

Mar 21, 2026

Mar 20, 2026

Zentalis Pharmaceuticals Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView

Mar 20, 2026

ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill

Mar 20, 2026

Mar 19, 2026

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Mar 19, 2026

Mar 18, 2026

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Analysts at Wells Fargo & Company - Defense World

Mar 18, 2026

Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday - MarketBeat

Mar 18, 2026

Mar 17, 2026

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Bitget

Mar 17, 2026

Triple-Negative breast and Cyclin E1 ovarian cancer data headed to AACR 2026 - Stock Titan

Mar 17, 2026

Tech Rally: Can Zentalis Pharmaceuticals Inc expand its profit margins - baoquankhu1.vn

Mar 17, 2026

Wells Fargo & Company Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) - MarketBeat

Mar 17, 2026

Wells Fargo assumes coverage on Zentalis stock with $5 target By Investing.com - Investing.com Canada

Mar 17, 2026

Mar 15, 2026